Multipoint Kras oncogene mutations potentially indicate mucinous carcinoma on the entire spectrum of mucinous ovarian neoplasms

• Published in: Oncotarget Vol. 7; no. 50; pp. 82097 - 82103
• Main Authors: Lee, Yi-Ju, Lee, Ming-Yung, Ruan, Alexandra, Chen, Chi-Kuan, Liu, Hao-Ping, Wang, Chau-Jong, Chao, Wan-Ru, Han, Chih-Ping
• Format: Journal Article
• Language: English
• Published: United States Impact Journals LLC 13.12.2016
• Subjects: Adenoma - genetics; Adenoma - pathology; Biomarkers, Tumor - genetics; Carcinoma - genetics; Carcinoma - pathology; Cell Transformation, Neoplastic - genetics; Cell Transformation, Neoplastic - pathology; DNA Mutational Analysis; Female; Genetic Predisposition to Disease; Humans; Mutation; Neoplasms, Cystic, Mucinous, and Serous - genetics; Neoplasms, Cystic, Mucinous, and Serous - pathology; Ovarian Neoplasms - genetics; Ovarian Neoplasms - pathology; Phenotype; Proto-Oncogene Proteins p21(ras) - genetics; Research Paper: Pathology; mucinous borderline tumor (MBT); mucinous carcinoma (MC); Pathology Section; anti-epidermal growth factor receptor (anti-EGFR); mucinous adenoma (MA)

Kras mutation is a common phenomenon in many human neoplasms. We aimed to assess the Kras mutational status along the histological continuum from normal ovaries to the development of benign, borderline and malignant ovarian mucinous neoplasms. We analyzed 41 cases of malignant, 10 cases of borderlin...